Founded in 2019, Beckley Psytech is a for-profit company dedicated to helping patients suffering from neurological and psychiatric disorders by developing a pipeline of psychedelic compounds into licensed pharmaceutical medicines.
Our vision, supplemented by our partnership with the Beckley Foundation, is for clinically validated psychedelic medicines to be integrated into modern medical practice in order to help patients in need around the world suffering with these profoundly debilitating conditions.
Our vision, supplemented by our partnership with the Beckley Foundation, is for clinically validated psychedelic medicines to be integrated into modern medical practice in order to help patients in need around the world suffering with these profoundly debilitating conditions.
Location: United Kingdom, England, Oxford
Employees: 11-50
Total raised: $99.12M
Founded date: 2019
Investors 9
Funding Rounds 2
| Date | Series | Amount | Investors |
| 16.08.2021 | Series B | $80.2M | - |
| 23.12.2020 | - | $18.92M | - |
Mentions in press and media 20
| Date | Title | Description |
| 02.06.2025 | atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies | NEW YORK and BERLIN and OXFORD, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health trea... |
| 27.03.2023 | Here are the 15 hottest startups in the psychedelics industry, according to top investors | From left: Sherry Rais, a cofounder and the CEO of Enthea; Mark Rus, the CEO of Delix Therapeutics; Jackie von Salm, a cofounder and the CSO of Psilera; Jimmy Qian, a cofounder and the president of Osmind. Sherry Rais/Enthea; Mark Rus/Delix... |
| 17.02.2023 | These investor-backed mental health startups are healing our brains | At least 1 in 5 people will experience mental illness at any time. Yet for many, treatment is prohibitive due to long-waiting lists for mental health professionals, hospital bed shortages, and medication that comes with adverse side effects... |
| 02.11.2021 | Beckley Psytech to present at Jefferies 2021 London Healthcare Conference | Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announces that Cosmo Feilding Mellen, Chief Executive Officer, will present at t... |
| 23.08.2021 | Digital health news, funding roundup in the prior week; August 23 | Maven Clinic raised $110M; Beckley Psytech landed $80M; Carrot Fertility secured $75M; ClosedLoop.ai Maven Clinic: Maven Clinic is a NY- based female founded digital health company which focused on women's and family health. Maven Clinic an... |
| 17.08.2021 | Beckley Psytech scoops up $80M Series B | Beckley Psytech has raised $80 million in an upsized round led by Integrated. The Oxford, UK-based startup uses psychedelic medicines to treat neurological and psychiatric disorders. The capital will go toward funding clinical trials. Addit... |
| 16.08.2021 | Beckley Psytech : completes oversubscribed $80m (£58m) fundraise to develop portfolio of psychedelic medicine breakthroughs | Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announced it has successfully completed an oversubscribed Series B financing, ra... |
| 16.08.2021 | UK-based Beckley Psytech aims to treat depression using a psychedelic agent found in toad venom; raises €67.8M | UK-based Beckley Psytech, with its deep ties to drug policy think tank Beckley Foundation, is a for-profit company with a mission to help patients suffering from neurological and psychiatric disorders. The company is developing a pipeline o... |
| 16.08.2021 | Beckley Psytech bags $80M to fuel psychedelics for depression, debilitating headaches | One year after raising a modest £3 million round, Beckley Psytech scored £58 million ($80 million) to get two psychedelics-based programs through the clinic. With the funding, the Oxford, U.K.-based biotech will complete a phase 1b study of... |
| 16.08.2021 | Oxford-based Beckley Psytech lands €49 million to develop psychedelic medicine breakthroughs | Photo from The Beckley Foundation Beckley Psytech, a British startup addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announced it has successfully completed an oversubscribed S... |
Show more